30595-79-0

Usage

Chemical Properties

white to slightly yellow crystalline powder,

InChI:InChI=1/C8H8Cl2O/c9-7-2-1-3-8(10)6(7)4-5-11/h1-3,11H,4-5H2

Upstream product

• 6575-24-2 2-(2,6-dichlorophenyl)acetic acid 
• 54551-83-6 methyl 2-(2,6-dichlorophenyl)acetate 

Downstream Products

• 144822-82-2 4-hydroxy-2,3-dihydrobenzofuran 
• 209256-42-8 2,3-dihydro-1-benzofuran-4-carbaldehyde 
• 609799-22-6 [14C]-Tasimelteon 
• 209257-15-8 1-[(1R,2R)-2-(2,3-dihydro-1-benzofuran-4-yl)cyclopropyl]methanamine 
• 29096-65-9 β-<2,6-Dichlorphenyl>-aethylamino-guanidin 
• 46398-59-8 β-(2,6-Dichlorphenyl)-ethylidenaminoguanidin 
• 230642-84-9 4-ethenyl-2,3-dihydro-1-benzofuran 
• 61698-06-4 3-(2,6-dichlorophenyl)propanenitrile 
• 936946-50-8 2-[2-(2,6-dichloro-phenyl)-ethyl]-thiazole-4-carboxylic acid ethyl ester 
• 871326-60-2 2-[2-(2,6-dichloro-phenyl)-ethyl]-thiazole-4-carboxylic acid 
• 736971-27-0 3-(2,6-dichlorophenyl)propanethioamide 
• 181472-07-1 2-(2,6-dichlorophenyl)-1-iodoethane 
• 118-69-4 2,6-dichlorotoluene 
• 28469-92-3 2,6-dichlorostyrene 

Relevant academic research and scientific papers

Imidazo ring PAR4 antagonist and medical applications thereof

The invention relates to an imidazo ring compound represented by formula (I) or formula (II), or a pharmaceutically acceptable salt or ester or solvate thereof. The compound disclosed by the inventioncan be used for preparing medicines for preventing or treating thromboembolic diseases.

RENIN INHIBITORS

The present invention relates to novel renin inhibitors of general formula (1), novel intermediates involved in their synthesis, their pharmaceutically acceptable salts and pharmaceutical compositions containing them. The present invention also relates to a process of preparing compounds of general formula (1), their tautomeric forms, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, and novel intermediates involved in their synthesis.

Synthesis and biological studies of novel 2-aminoalkylethers as potential antiarrhythmic agents for the conversion of atrial fibrillation

A series of 2-aminoalkylethers prepared as potential antiarrhythmic agents is described. The present compounds are mixed sodium and potassium ion channel blockers and exhibit antiarrhythmic activity in a rat model of ischemia-induced arrhythmias. Structure-activity studies led to the identification of three compounds 5, 18, and 26, which were selected based on their particular in vivo electrophysiological properties, for studies in two canine atrial fibrillation (AF) models. The three compounds converted AF in both models, but only compound 26 was shown to be orally bioavailable. Resolution of the racemate 26 into its corresponding enantiomers 40 and 41 and subsequent biological testing of these enantiomers led to the selection of (1S,2S)-1-(1-naphthalenethoxy)-2-(3- ketopyrrolidinyl)cyclohexane monohydrochloride (41) as a potential atrial selective antiarrhythmic candidate for further development.

Synthesis and evaluation of thiazole carboxamides as vanilloid receptor 1 (TRPV1) antagonists

A thiazole derivative, 2-(2,6-dichlorobenzyl)-N-(4-isopropylphenyl) thiazole-4-carboxamide (1), was identified as a TRPV1 antagonist. We synthesized various thiazole analogs and evaluated them for their ability to block capsaicin- or acid-induced calcium influx in TRPV1-expressing CHO cells. The IC50 values of the most potent antagonists were ca. 0.050 μM in these assays.

AMINOCYCLOHEXYL ETHER COMPOUNDS AND USES THEREOF

Aminocyclohexyl ether compounds of formula (I), or a solvate or pharmaceutically acceptable salt thereof: are disclosed. In said formula, A, X and R, -R5 have the meanings given in the description. The compounds of the present invention may be inco